Buy & Sell AFLAC Incorporated (AFL) – AFLAC Incorporated Price Today
Aura AI Summary
Key Stats
- $58.66BMarket Cap
- FinancialsSector
- -5.53%3M Drawdown
- $67.32BEnterprise Value
- 2.12%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 95 daysTypical Hold Time
AFLAC Incorporated (AFL) is currently valued at a market capitalization of $58.66B, with an enterprise value of $67.32B. Over the past 52 weeks, AFLAC Incorporated has traded between a low of $98.09 and a high of $118.67, highlighting its annual price range. Over the past three months, AFLAC Incorporated has recorded a drawdown of -5.53%, reflecting recent price volatility. AFLAC Incorporated offers a dividend yield of 2.12%, with the most recent dividend of $0.61 paid on 20 May 26. On average, investors hold AFLAC Incorporated for approximately 95 days, indicating typical investor behavior on the platform.
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Most Recent News
Gilead and Merck halt lung cancer trial but report positive HIV drug Phase 3 results.
Gilead Sciences and Merck have stopped their Phase 3 trial combining Trodelvy and Keytruda for metastatic non-small cell lung cancer after it failed to show statistically significant benefits. However, they announced positive Phase 3 results for a ne...
American Airlines signs largest sustainable aviation fuel deal with Google, boosting stock.
American Airlines has signed the largest sustainable aviation fuel (SAF) certificate agreement with Google, securing 35 million gallons of SAF over three years to reduce nearly 300,000 metric tons of CO₂ emissions. This deal supports American Airline...
Over 29 pharma firms advance 35+ Treg cell therapies, promising new treatments for autoimmune and transplant diseases.
The Treg cell-based therapies pipeline is robust with more than 29 pharmaceutical companies developing over 35 therapies targeting autoimmune diseases, graft-versus-host disease, and transplant rejection. Key players like Orca Bio, Cellenkos, and Que...